Induction of glutathione synthesis and conjugation by 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-dihydroxymethamphetamine (HHMA) in human and rat liver cells, including the protective role of some antioxidants

Toxicology

Volumn 289, Issue 2-3, 2011, Pages 175-184

  Antolino Lobo, Irene ^a,b   Meulenbelt, Jan ^a,b,c   Molendijk, Jeffrey ^a   Nijmeijer, Sandra M ^a   Scherpenisse, Peter ^a   Van Den Berg, Martin ^a   Van Duursen, Majorie B M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

GCL; Antioxidant; GSH; GST; MDMA; PXR

Indexed keywords

3,4 DIHYDROXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; ACETYLCYSTEINE; GLUTAMATE CYSTEINE LIGASE; GLUTAMATE CYSTEINE LIGASE CATALYTIC SUBUNIT; GLUTATHIONE; GLUTATHIONE TRANSFERASE; MESSENGER RNA; METHAMPHETAMINE; PREGNANE X RECEPTOR; PROTEIN SUBUNIT; SULFORAPHANE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL PROTECTION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; EPITHELIUM CELL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; IC 50; LIVER CELL; LIVER LEVEL; LIVER METABOLISM; LIVER PROTECTION; LIVER TOXICITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT;

ANIMALS; ANTIOXIDANTS; CELL SURVIVAL; CELLS, CULTURED; DEOXYEPINEPHRINE; DRUG INTERACTIONS; GLUTATHIONE; HEPATOCYTES; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PROTECTIVE AGENTS; RATS; RATS, WISTAR;

RATTUS;

EID: 80052722941     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2011.08.012     Document Type: Article

References (55)

1. Andreu V., Mas A., Bruguera M., Salmeron J.M., Moreno V., Nogue S., Rodes J. Ecstasy: a common cause of severe acute hepatotoxicity. J. Hepatol. 1998, 29:394-397.
2. Antolino-Lobo I., Meulenbelt J., Nijmeijer S.M., Maas-Bakker R.F., Meijerman I., van den Berg M., van Duursen M.B. 3,4-Methylenedioxymethamphetamine (MDMA) interacts with therapeutic drugs on CYP3A by inhibition of pregnane X receptor (PXR) activation and catalytic enzyme inhibition. Toxicol. Lett. 2011, 203:82-91.
3. Antolino-Lobo I., Meulenbelt J., Nijmeijer S.M., Scherpenisse P., van den Berg M., van Duursen M.B. Differential roles of phase I and phase II enzymes in 3,4-methylendioxymethamphetamine-induced cytotoxicity. Drug Metab. Dispos. 2010, 38:1105-1112.
4. Blumberg B., Sabbagh W., Juguilon H., Bolado J., van Meter C.M., Ong E.S., Evans R.M. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev. 1998, 12:3195-3205.
5. Capela J.P, Macedo C., Branco P.S., Ferreira L.M., Lobo A.M., Fernandes E., Remiao F., Bastos M.L., Dirnagl U., Meisel A., Carvalho F. Neurotoxicity mechanisms of thioether ecstasy metabolites. Neuroscience 2007, 146:1743-1757.
6. Carmo H., Brulport M., Hermes M., Oesch F., Silva R., Ferreira L.M., Branco P.S., Boer D., Remiao F., Carvalho F., Schon M.R., Krebsfaenger N., Doehmer J., Bastos Mde L., Hengstler J.G. Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine ('Ecstasy') cytotoxicity. Pharmacogenet. Genomics 2006, 16:789-799.
7. Carvalho M., Hawksworth G., Milhazes N., Borges F., Monks T.J., Fernandes E., Carvalho F., Bastos M.L. Role of metabolites in MDMA (ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renal proximal tubular cells. Arch. Toxicol. 2002, 76:581-588.
8. Carvalho M., Milhazes N., Remiao F., Borges F., Fernandes E., Amado F., Monks T.J., Carvalho F., Bastos M.L. Hepatotoxicity of 3,4-methylenedioxyamphetamine and alpha-methyldopamine in isolated rat hepatocytes: formation of glutathione conjugates. Arch. Toxicol. 2004, 78:16-24.
9. Carvalho M., Pontes H., Remiao F., Bastos M.L., Carvalho F. Mechanisms underlying the hepatotoxic effects of ecstasy. Curr. Pharm. Biotechnol. 2010, 11:476-495.
10. Carvalho M., Remiao F., Milhazes N., Borges F., Fernandes E., Carvalho F., Bastos M.L. The toxicity of N-methyl-alpha-methyldopamine to freshly isolated rat hepatocytes is prevented by ascorbic acid and N-acetylcysteine. Toxicology 2004, 200:193-203.
11. Carvalho M., Remiao F., Milhazes N., Borges F., Fernandes E., Monteiro Mdo C., Goncalves M.J., Seabra V., Amado F., Carvalho F., Bastos M.L. Metabolism is required for the expression of ecstasy-induced cardiotoxicity in vitro. Chem. Res. Toxicol. 2004, 17:623-632.
12. Chen Y., Johansson E., Yang Y., Miller M.L., Shen D., Orlicky D.J., Shertzer H.G., Vasiliou V., Nebert D.W., Dalton T.P. Oral N-acetylcysteine rescues lethality of hepatocyte-specific Gclc-knockout mice, providing a model for hepatic cirrhosis. J. Hepatol. 2010, 53:1085-1094.
13. Cho A.K., Hiramatsu M., Distefano E.W., Chang A.S., Jenden D.J. Stereochemical differences in the metabolism of 3,4-methylenedioxymethamphetamine in vivo and in vitro: a pharmacokinetic analysis. Drug Metab. Dispos. 1990, 18:686-691.
14. de la Torre R., Farre M., Ortuno J., Mas M., Brenneisen R., Roset P.N., Segura J., Cami J. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br. J. Clin. Pharmacol. 2000, 49:104-109.
15. de la Torre R., Farre M., Roset P.N., Pizarro N., Abanades S., Segura M., Segura J., Cami J. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther. Drug Monit. 2004, 26:137-144.
16. Dussault I., Forman B.M. The nuclear receptor PXR: a master regulator of " homeland" defense. Crit. Rev. Eukaryot. Gene Expr. 2002, 12:53-64.
17. Easton N., Fry J., O'Shea E., Watkins A., Kingston S., Marsden C.A. Synthesis, in vitro formation, and behavioural effects of glutathione regioisomers of alpha-methyldopamine with relevance to MDA and MDMA (ecstasy). Brain Res. 2003, 987:144-154.
18. Easton N., Marsden C.A. Ecstasy: are animal data consistent between species and can they translate to humans?. J. Psychopharmacol. 2006, 20:194-210.
19. EMCDDA, 2008. Annual report, 2008: the state of the drugs problem in Europe. L.O.f.O.P.o.t.E.C.I. 978-92-9168-324-6. European Monitoring Center for Drugs and Drugs Addiction.
20. Fimognari C., Lenzi M., Hrelia P. Interaction of the isothiocyanate sulforaphane with drug disposition and metabolism: pharmacological and toxicological implications. Curr. Drug Metab. 2008, 9:668-678.
21. Gao X., Dinkova-Kostova A.T., Talalay P. Powerful and prolonged protection of human retinal pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: the indirect antioxidant effects of sulforaphane. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:15221-15226.
22. Garcia-Repetto R., Moreno E., Soriano T., Jurado C., Gimenez M.P., Menendez M. Tissue concentrations of MDMA and its metabolite MDA in three fatal cases of overdose. Forensic Sci. Int. 2003, 135:110-114.
23. Gong H., Singh S.V., Singh S.P., Mu Y., Lee J.H., Saini S.P.S., Toma D., Ren S., Kagan V.E., Day B.W., Zimniak P., Xie W. Orphan nuclear receptor pregnane X receptor sensitizes oxidative stress responses in transgenic mice and cancerous cells. Mol. Endocrinol. 2006, 20:279-290.
24. Griffith O.W. Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic. Biol. Med. 1999, 27:922-935.
25. Gross-Steinmeyer K., Stapleton P.L., Tracy J.H., Bammler T.K., Strom S.C., Eaton D.L. Sulforaphane- and phenethyl isothiocyanate-induced inhibition of aflatoxin B1-mediated genotoxicity in human hepatocytes: role of GSTM1 genotype and CYP3A4 gene expression. Toxicol. Sci. 2010, 116:422-432.
26. Guerrero-Beltran C.E., Calderon-Oliver M., Martinez-Abundis E., Tapia E., Zarco-Marquez G., Zazueta C., Pedraza-Chaverri J. Protective effect of sulforaphane against cisplatin-induced mitochondrial alterations and impairment in the activity of NAD(P)H: quinone oxidoreductase 1 and gamma glutamyl cysteine ligase: studies in mitochondria isolated from rat kidney and in LLC-PK1 cells. Toxicol. Lett. 2010, 199:80-92.
27. Hewitt N.J., Lecluyse E.L., Ferguson S.S. Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica 2007, 37:1196-1224.
28. Huang Z.A, Yang H., Chen C., Zeng Z., Lu S.C. Inducers of gamma-glutamylcysteine synthetase and their effects on glutathione synthetase expression. Biochim. Biophys. Acta 2000, 1493:48-55.
29. Jones D.C., Duvauchelle C., Ikegami A., Olsen C.M., Lau S.S., de la Torre R., Monks T.J. Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. J. Pharmacol. Exp. Ther. 2005, 313:422-431.
30. Kang K.W., Lee S.J., Kim S.G. Molecular mechanism of nrf2 activation by oxidative stress. Antioxid. Redox Signal. 2005, 7:1664-1673.
31. Khakoo S.I., Coles C.J., Armstrong J.S., Barry R.E. Hepatotoxicity and accelerated fibrosis following 3,4-methylenedioxymetamphetamine (" ecstasy" ) usage. J. Clin. Gastroenterol. 1995, 20:244-247.
32. Kim B.-R., Hu R., Keum Y.-S., Hebbar V., Shen G., Nair S.S., Kong A.-T. Effects of glutathione on antioxidant response element-mediated gene expression and apoptosis elicited by sulforaphane. Cancer Res. 2003, 63:7520-7525.
33. Kliewer S.A., Goodwin B., Willson T.M. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr. Rev. 2002, 23:687-702.
34. Krejsa C.M., Franklin C.C., White C.C., Ledbetter J.A., Schieven G.L., Kavanagh T.J. Rapid activation of glutamate cysteine ligase following oxidative stress. J. Biol. Chem. 2010, 285:16116-16124.
35. Kreth K., Kovar K., Schwab M., Zanger U.M. Identification of the human cytochromes P450 involved in the oxidative metabolism of " Ecstasy" -related designer drugs. Biochem. Pharmacol. 2000, 59:1563-1571.
36. Krzywanski D.M., Dickinson D.A., Iles K.E., Wigley A.F., Franklin C.C., Liu R.M., Kavanagh T.J., Forman H.J. Variable regulation of glutamate cysteine ligase subunit proteins affects glutathione biosynthesis in response to oxidative stress. Arch. Biochem. Biophys. 2004, 423:116-125.
37. Lin L.Y., Kumagai Y., Cho A.K. Enzymatic and chemical demethylenation of (methylenedioxy)amphetamine and (methylenedioxy)methamphetamine by rat brain microsomes. Chem. Res. Toxicol. 1992, 5:401-406.
38. Lu S.C. Regulation of glutathione synthesis. Mol. Aspects Med. 2009, 30:42-59.
39. Malpass A., White J.M., Irvine R.J., Somogyi A.A., Bochner F. Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and Dark Agouti rats. Pharmacol. Biochem. Behav. 1999, 64:29-34.
40. Maurer H.H., Bickeboeller-Friedrich J., Kraemer T., Peters F.T. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). Toxicol. Lett. 2000, 112-113:133-142.
41. McWalter G.K., Higgins L.G., McLellan L.I., Henderson C.J., Song L., Thornalley P.J., Itoh K., Yamamoto M., Hayes J.D. Transcription factor Nrf2 is essential for induction of NAD(P)H:quinone oxidoreductase 1, glutathione-S-transferases, and glutamate cysteine ligase by broccoli seeds and isothiocyanates. J. Nutr. 2004, 134:3499S-3506S.
42. Meyer M.R., Peters F.T., Maurer H.H. The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers. Drug Metab. Dispos. 2008, 36:2345-2354.
43. Milhazes N., Cunha-Oliveira T., Martins P., Garrido J., Oliveira C., Rego A.C., Borges F. Synthesis and cytotoxic profile of 3,4-methylenedioxymethamphetamine (" ecstasy" ) and its metabolites on undifferentiated PC12 cells: a putative structure-toxicity relationship. Chem. Res. Toxicol. 2006, 19:1294-1304.
44. Monks T.J., Lau S.S. Biological reactivity of polyphenolic-glutathione conjugates. Chem. Res. Toxicol. 1997, 10:1296-1313.
45. Moradi M., Mojtahedzadeh M., Mandegari A., Soltan-Sharifi M.S., Najafi A., Khajavi M.R., Hajibabayee M., Ghahremani M.H. The role of glutathione-S-transferase polymorphisms on clinical outcome of ALI/ARDS patient treated with N-acetylcysteine. Respir. Med. 2009, 103:434-441.
46. Pizarro N., de la Torre R., Joglar J., Okumura N., Perfetti X., Lau S.S., Monks T.J. Serotonergic neurotoxic thioether metabolites of 3,4-methylenedioxymethamphetamine (MDMA, " ecstasy" ): synthesis, isolation, and characterization of diastereoisomers. Chem. Res. Toxicol. 2008, 21:2272-2279.
47. Segura M., Ortuno J., Farre M., McLure J.A., Pujadas M., Pizarro N., Llebaria A., Joglar J., Roset P.N., Segura J., de La Torre R. 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem. Res. Toxicol. 2001, 14:1203-1208.
48. Sevgiler Y., Uner N. Tissue-specific effects of fenthion on glutathione metabolism modulated by NAC and BSO in Oreochromis niloticus. Drug Chem. Toxicol. 2010, 33:348-356.
49. Synold T.W., Dussault I., Forman B.M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med. 2001, 7:584-590.
50. Treijtel N., Barendregt A., Freidig A.P., Blaauboer B.J., van Eijkeren J.C. Modeling the in vitro intrinsic clearance of the slowly metabolized compound tolbutamide determined in sandwich-cultured rat hepatocytes. Drug Metab. Dispos. 2004, 32:884-891.
51. Tucker G.T., Lennard M.S., Ellis S.W., Woods H.F., Cho A.K., Lin L.Y., Hiratsuka A., Schmitz D.A., Chu T.Y. The demethylenation of methylenedioxymethamphetamine (" ecstasy" ) by debrisoquine hydroxylase (CYP2D6). Biochem. Pharmacol. 1994, 47:1151-1156.
52. Xu C., Li C.Y., Kong A.-T. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 2005, 28:249-268.
53. Yeh J.Y., Cheng L.C., Ou B.R., Whanger P.D., Chang L.W. Differential influences of various arsenic compounds on glutathione redox status and antioxidative enzymes in porcine endothelial cells. Cell. Mol. Life Sci. 2002, 59:1972-1982.
54. Zhang Y., Callaway E.C. High cellular accumulation of sulphoraphane, a dietary anticarcinogen, is followed by rapid transporter-mediated export as a glutathione conjugate. Biochem. J. 2002, 364:301-307.
55. Zhou C., Poulton E.J., Grun F., Bammler T.K., Blumberg B., Thummel K.E., Eaton D.L. The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. Mol. Pharmacol. 2007, 71:220-229.